MESA LABORATORIES INC CO
For the period ended Dec 31, 2023. Filed Feb 5, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2023 · Filed Feb 5, 2024
MLAB$136.91+7.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
M****esa Laboratories, Inc.**
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Nine Months Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash flows from operating activities: | ||
| Net income | $337 | $319 |
| Adjustments to reconcile net income to net cash from operating activities: | ||
| Depreciation of property, plant and equipment | 2,899 | 3,196 |
| Amortization of acquisition-related intangibles | 22,380 | 21,573 |
| Stock-based compensation expense | 9,144 | 9,859 |
| Non-cash interest and debt amortization | 692 | 679 |
| Other | (1,614) | (1,038) |
| Cash from changes in operating assets and liabilities: | ||
| Accounts receivable, net | 8,294 | (1,979) |
| Inventories | 217 | (9,191) |
| Prepaid expenses and other assets | (7,841) | (2,312) |
| Accounts payable | (1,656) | (1,339) |
| Accrued liabilities and taxes payable | (124) | (5,221) |
| Unearned revenues | (1,478) | 918 |
| Net cash provided by operating activities | 31,250 | 15,464 |
| Cash flows from investing activities: | ||
| Acquisitions, net of cash acquired | (79,700) | (4,950) |
| Purchases of property, plant and equipment | (2,032) | (3,518) |
| Net cash (used in) investing activities | (81,732) | (8,468) |
| Cash flows from financing activities: | ||
| Proceeds from the issuance of debt | 71,000 | - |
| Repayment of debt | (22,000) | (30,000) |
| Dividends paid | (2,583) | (2,550) |
| Proceeds from the exercise of stock options | 358 | 4,523 |
| Payment of tax withholding obligation on vesting of restricted stock | (726) | (909) |
| Other financing, net | (280) | - |
| Net cash provided by (used in) financing activities | 45,769 | (28,936) |
| Effect of exchange rate changes on cash and cash equivalents | 27 | (1,305) |
| Net (decrease) in cash and cash equivalents | (4,686) | (23,245) |
| Cash and cash equivalents at beginning of period | 32,910 | 49,346 |
| Cash and cash equivalents at end of period | $28,224 | $26,101 |
| Supplemental non-cash activity: | |||
|---|---|---|---|
| Acquisition-related consideration held back against potential indemnification losses | $9,526 | $ | - |
See accompanying notes to Condensed Consolidated Financial Statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.